THE REGENTIME* PROCEDURE, A SAFE WAY FOR REGENERATION

Nassim H. Abi Chahine

The Lebanese-Canadian Hospital, Beirut, Lebanon

Abstract

Over a period of six years, three hundred patients with different types of diseases were monitored before and after the treatment with Regentime procedure.

The procedure consists of transplantation of in vivo Proliferated and Mobilized Autologous Adult Bone Marrow Derived Human Progenitor Cells post-in-vitro incubation with organ-specific xeno-ultrafiltrates and their subsequent partial differentiation.

The study encircled a range of chronic deteriorating diseases, like dementia, Parkinson's disease, diabetes type 1, cardiac failure, liver cirrhosis, joints degeneration and others, as well as acute diseases like intoxication, hypoxemia leading to brain stroke or cardiac infarct and spinal cord injury in its different types, cerebral palsy, multiple sclerosis and many others, having the tissue degeneration as a common pathophysiological feature.

Autologous bone marrow stem cells were outsourcing all therapeutic acts. The aim of our research was to monitor this transplantation protocol of and its results. We notably studied the biological preparation of the donor and the receptor area, cells processing, incubation and transplantation. We understood new phenomena and many previously un-described cell behaviors. Several phases have been achieved. As long as progenitor cell transplantation is an innovative medical therapy; our team designed many steps facilitating its success. Moreover this work, as the previous one, presented in 2015 and in 2016, unmasks prime evidences including stem cell transformation following incubation with ultra-filtrates, the organ-specific amino-acids, reminding followers about the Regentime Equation facilitating the estimation of biological improvement following this applied treatment in many different cases.

We showed in a palpable way that adult autologous progenitor cell transplantation is relatively an efficient treatment and not only in degenerating diseases, but also in a wide selection of tumors and immune diseases. We are paving the road to our colleagues in the clinical, therapeutic and academic ground to safely and undoubtedly use this way of treatment.

*Registered Trade Mark in Lebanon.